The Future of Biotech: Syngene's US Acquisition Sets the Stage

Syngene International has bought its first US biologics plant from Emergent BioSolutions for $36.5 million as part of an overall investment of $50 million. The acquisition increases Syngene's capacity for single-use bioreactors to 50,000 liters, increasing its large molecule discovery and manufacturing capacities. Strategically positioned close to major biotech clusters, the unit will become functional by the second half of 2025. This deal marks Syngene's move towards global expansion, providing end-to-end services in human and animal health segments, and aligns with India's strategy to minimize dependence on China by increasing capabilities in other areas.

 

Source: Business Standard, Reuters, Moneycontrol, PR Newswire